| TGA Category | Cat. 3 |
| SIZE | 30ml |
| RRP | $99 |
Most medicinal cannabis products are not approved by the TGA and therefore there are no approved indications in Australia. Medicinal cannabis has been used to treat the several medical conditions (this is not an exclusive list of conditions and is a summary of the general recommendations taken from literature sources; doses are for guidance only). The TGA has produced guidance documents on the use of medicinal cannabis in a range of different conditions which are available at: https://www.tga.gov.au/medicinal-cannabis-guidance-documents.
1. Therapeutic Goods Administration (TGA). “Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia”. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents. Accessed January 2024. 2. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020;12(3):129-141. doi: 10.14740/jocmr4090. 3. Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review, NeuroToxicology. 2019; 74:282-298. doi:10.1016/j.neuro.2019.08.002. 4. Therapeutic Goods Administration (TGA). Guidance for the use of medicinal cannabis in the treatment of multiple sclerosis in Australia. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents. Accessed February 2022. 5. Therapeutic Goods Administration (TGA). Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents. Accessed January 2024. 6. Suraev A, Mills L, Abelev SV, Arkell TR, Lintzeris N, McGregor IS. Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nat Sci Sleep. 2023;15:245-255. doi: 10.2147/NSS.S390583. 7. Razmovski-Naumovski V, Luckett T, Amgarth-Duff I, Agar MR. Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review. Palliat Med. 2022;36(6):912-927. doi: 10.1177/02692163221083437 8. Therapeutic Goods Administration (TGA). Guidance for the use of medicinal cannabis in the prevention and management nausea and vomiting in Australia. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents 9. Therapeutic Goods Administration (TGA). Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents 10. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018; 49: 12-19. 11. Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021; 3(1): 22.